Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic
Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide [...]